- Home
- ARQ vs ADAP Comparison
ARQ vs ADAP Comparison
Compare ARQ & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQ
- ADAP
- Stock Information
- Founded
- ARQ 1996
- ADAP 2008
- Country
- ARQ United States
- ADAP United Kingdom
- Employees
- ARQ N/A
- ADAP N/A
- Industry
- ARQ
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- ARQ
- ADAP Health Care
- Exchange
- ARQ NYSE
- ADAP Nasdaq
- Market Cap
- ARQ 249.0M
- ADAP 212.3M
- IPO Year
- ARQ N/A
- ADAP 2015
- Fundamental
- Price
- ARQ $6.89
- ADAP $0.59
- Analyst Decision
- ARQ
- ADAP Strong Buy
- Analyst Count
- ARQ 0
- ADAP 4
- Target Price
- ARQ N/A
- ADAP $3.16
- AVG Volume (30 Days)
- ARQ 242.2K
- ADAP 2.0M
- Earning Date
- ARQ 11-07-2024
- ADAP 11-13-2024
- Dividend Yield
- ARQ N/A
- ADAP N/A
- EPS Growth
- ARQ N/A
- ADAP N/A
- EPS
- ARQ N/A
- ADAP N/A
- Revenue
- ARQ $110,023,000.00
- ADAP $175,041,000.00
- Revenue This Year
- ARQ $6.31
- ADAP $180.15
- Revenue Next Year
- ARQ $31.95
- ADAP N/A
- P/E Ratio
- ARQ N/A
- ADAP N/A
- Revenue Growth
- ARQ 16.44
- ADAP 146.27
- 52 Week Low
- ARQ $2.31
- ADAP $0.42
- 52 Week High
- ARQ $8.26
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- ARQ 65.39
- ADAP 26.22
- Support Level
- ARQ $6.54
- ADAP $0.75
- Resistance Level
- ARQ $7.21
- ADAP $0.83
- Average True Range (ATR)
- ARQ 0.27
- ADAP 0.07
- MACD
- ARQ 0.09
- ADAP -0.01
- Stochastic Oscillator
- ARQ 78.81
- ADAP 2.36
About ARQ ARQ INC
Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granular Activated Carbon, and Colloidal Carbon Product among others.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.